AMPLIFY-7P missed its primary endpoint; a post-hoc R0 subgroup signal now carries the entire PDAC vaccine bet, with $23M covering roughly one more quarter

Elicio is a clinical-stage biotech developing a vaccine for pancreatic cancer that is not yet approved, though a late-stage trial recently missed its primary effectiveness target in the overall patient group and now relies on a subset analysis to advance.

Elicio built a mKRAS-targeting amphiphile vaccine for one of oncology's hardest diseases, pancreatic cancer, where most patients relapse within a year of surgery. AMPLIFY-7P missed its ITT primary endpoint, and the entire remaining case rests on whether regulators and investors accept a post-hoc R0 subgroup result (HR 0.65, p=0.048) as the basis for a Phase 3 that the company cannot fund beyond Q1 2027. With $23M on hand and $10.4M quarterly burn, capital exhaustion arrives before any Phase 3 efficacy data.